Immune Pharmaceuticals has completed its merger with EpiCept. The merger combines Immune's antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept's early-stage cancer program and its late-stage topical pain product, AmiKet.
Iin connection with the closing of the merger, the composition of the company's board of directors has increased to seven. Daniel Teper, chief executive officer, has joined the board of directors as chairman. David Sidransky, professor of oncology at the Johns Hopkins School of Medicine, has been appointed vice chairman. Ana Stancic has been named the chairperson of the audit committee. Isaac Kobrin, Herve de Kergrohen and Pierre Albouy also have been named to the company's board.
Robert Cook, EpiCept's previous interim president and chief executive officer, retains his position on the board and has been named chief financial officer. Alan Dunton, previous non-executive chairman of EpiCept, Robert Savage and Keith Brownlie have resigned their positions.